Madrigal Pharmaceuticals, Inc. MDGL
396.78 USD -1.31 (-0.33%)
As ofNov 19, 2026, 1:06 PM EST
395.56 Day range 411.13
353.54 52-week range 615.00
- YTD
- -31.87%
- 1 year
- -28.59%
News
prnewswire.com MDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity Concerns SAN FRANCISCO, Nov. 19, 2026 /PRNewswire/ -- Hagens Berman, a national complex securities litigation law firm, announces an investigation into Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL). The…benzinga.com Sonic Incytes Medical Announces Multi-Year Partnership With Madrigal Pharma To Advance Assessment And Risk Stratification Of Patients With Or At Risk For MASH Partnership aims to help more clinicians assess and risk-stratify patients with or at risk for metabolic dysfunction-associated steatohepatitis (MASH), using point-of-care liver assessment.Sonic…
newsfilecorp.com Kaplan Fox Reminds Madrigal Pharmaceuticals, Inc. (MDGL) Investors of an Investigation into Potential Securities Law Violations New York, New York--(Newsfile Corp. - November 19, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company")…
globenewswire.com Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic…
globenewswire.com Kaplan Fox & Kilsheimer LLP is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations NEW YORK, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ:…
newsfilecorp.com Madrigal Pharmaceuticals, Inc. Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your MDGL Investments New York, New York--(Newsfile Corp. - November 18, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company")…
newsfilecorp.com Kaplan Fox & Kilsheimer LLP Alerts Investors of Madrigal Pharmaceuticals, Inc. (MDGL) to an Investigation of Potential Securities Law Violations New York, New York--(Newsfile Corp. - November 18, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company")…
prnewswire.com MDGL Investigation Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP RADNOR, Pa., Nov. 17, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the…
seekingalpha.com Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies Global Healthcare Conference 2026 Transcript Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
newsfilecorp.com Kaplan Fox Notifies Madrigal Pharmaceuticals, Inc. (MDGL) Investors of a Securities Investigation into the Company New York, New York--(Newsfile Corp. - November 17, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company")…
globenewswire.com Kaplan Fox Reminds Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Contact the Firm Regarding an Investigation of Potential Securities Law Violations NEW YORK, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ:…
newsfilecorp.com Kaplan Fox is Investigating Madrigal Pharmaceuticals, Inc. (MDGL) on Behalf of Investors for Potential Securities Law Violations New York, New York--(Newsfile Corp. - November 16, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company")…
globenewswire.com MDGL Investigation Notification: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP RADNOR, Pa., Nov. 14, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the…
globenewswire.com Kaplan Fox is Investigating Claims on Behalf of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors for Potential Securities Law Violations NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ:…
newsfilecorp.com Kaplan Fox is Investigating Madrigal Pharmaceuticals, Inc. (MDGL) and Encourages Investors Who Suffered Losses to Contact the Firm New York, New York--(Newsfile Corp. - November 13, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company")…
globenewswire.com Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences CONSHOHOCKEN, Pa., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor…
newsfilecorp.com Kaplan Fox & Kilsheimer LLP Announces an Investigation into Madrigal Pharmaceuticals, Inc. (MDGL) for Possible Securities Law Violations New York, New York--(Newsfile Corp. - November 12, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company")…benzinga.com Madrigal Pharmaceuticals Announces Data From Its Rezdiffra Trials Demonstrated 55% Participants Achieved Over 25% Improvement In Liver Stiffness, 48% Patients Reports Over 30% Improvement At 12 Months Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced…
benzinga.com Top 3 Health Care Stocks You'll Regret Missing In Q4 Healthcare stocks Alnylam, Madrigal and Corcept appear oversold, with RSI near or below 30, offering potential opportunities for investors.benzinga.com Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $633 Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $612 to $633.
benzinga.com Truist Securities Reiterates Buy on Madrigal Pharmaceuticals, Raises Price Target to $743 Truist Securities analyst Srikripa Devarakonda reiterates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $709 to $743.
benzinga.com Citigroup Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $760 Citigroup analyst Eric Joseph maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $725 to $760.
benzinga.com Madrigal Pharmaceuticals Q3 2026 Earnings Call Transcript Madrigal Pharmaceuticals (NASDAQ:MDGL) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Madrigal Pharmaceuticals Q3 EPS $1.83 Beats $(0.94) Estimate, Sales $431.268M Beat $404.264M Estimate Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $(0.94) by 294.68 percent. This is a 136.02 percent increase over…
